| (USD) | Dec 2023 | Q/Q |
|---|---|---|
| Revenue | 38MM | +37% |
| Gross Profit | 32.4MM | - |
| Cost Of Revenue | 5.6MM | +65% |
| Operating Income | -247.3MM | - |
| Operating Expenses | 279.7MM | - |
| Net Income | -217.8MM | - |
| R&D | 1MM | -16% |
| G&A | 22.2MM | -4% |
| Amortization | 7.7MM | - |
| Interest Expense | 8.2MM | +3% |
Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes from
FinraMoving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.
Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.
PEARL RIVER, N.Y., April 15, 2024--Acorda Therapeutics Announces Delisting from Nasdaq
(Bloomberg) -- The junkiest corporate debt is becoming increasingly hazardous for investors amid mounting signs that a default cycle is picking up steam. Most Read from BloombergTrumpism Is Emptying ChurchesRBC Fires CFO Ahn After Probe Into Personal RelationshipThe Odds of $100 Oil Are Rising as Supply Shocks Convulse the MarketSaudis Scale Back Ambition for $1.5 Trillion Desert Project NeomIsrael Backs Out of Khan Younis to Prepare ‘Future Operations’The holding company of Thames Water Ltd. th
PEARL RIVER, N.Y., April 03, 2024--Acorda Therapeutics Announces Nasdaq Delisting Notification
Stalking horse bidder Merz Therapeutics could get rights to Acorda’s three marketed drugs if its $185 million proposal holds.
PEARL RIVER, N.Y., April 01, 2024--Acorda Therapeutics and Merz Announce Signing of "Stalking Horse" Asset Purchase Agreement
PEARL RIVER, N.Y., April 01, 2024--Acorda Cancels Q4 and Year End 2023 Earnings Conference Call Scheduled for April 1, 2024
PEARL RIVER, N.Y., March 25, 2024--Acorda Fourth Quarter/Year End 2023 Update: Webcast/Conference Call Scheduled for April 1, 2024
PEARL RIVER, N.Y., January 11, 2024--Acorda Therapeutics to Regain Global Commercialization Rights to FAMPYRA® by January 2025
Acorda Therapeutics, Inc. ( NASDAQ:ACOR ) shareholders are no doubt pleased to see that the share price has bounced 53...
Acorda Therapeutics, Inc. (NASDAQ:ACOR) Q3 2023 Earnings Call Transcript November 13, 2023 Operator: Welcome to Acorda Therapeutics Third Quarter 2023 Financial and Business Update. At this time, all participants are in a listen-only mode. There will be a question-and-answer session to follow. Please be advised that this call is being recorded at the company’s request. […]